{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-040251","form_type":"8-K","ticker":"INFU","cik":"0001337013","company_name":"InfuSystem Holdings, Inc","filed_at":"2024-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.708283+00:00","generated_at":"2026-05-31T05:12:03.971510+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"InfuSystem releases updated 2024 outlook: revenue ~$134.2M, Adj. EBITDA ~$26.5M","bullets":["2024 estimated net revenue of $134.2M (+6.7% YoY); Adj. EBITDA $26.5M (high-teens margin).","Recent distribution agreements: Smith+Nephew RENASYS EDGE NPWT system; exclusive U.S. ChemoMouthpiece with Sanara MedTech.","Patient Services revenue $77.3M (TTM 6/30/24); Device Solutions $52.1M; gross margins 64.9% and 29.4%.","Net leverage 1.53x; $40.5M total liquidity; $20M share repurchase program authorized.","Five consecutive years of record revenue; 12% revenue CAGR 2019-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-040251","json":"https://secwatch.observer/filing/0001628280-24-040251.json","markdown":"https://secwatch.observer/filing/0001628280-24-040251.md","text":"https://secwatch.observer/filing/0001628280-24-040251.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1337013/000162828024040251/0001628280-24-040251-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1337013/000162828024040251/infu-20240912.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:12:03.971510+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}